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Despite dramatic advances in the treatment of pediatric leukemia over the past 50 years,
there remain subsets of patients who respond poorly to treatment. Many of the high-risk
cases of childhood leukemia with the poorest prognosis have been found to harbor spe-
cific genetic signatures, often resulting from chromosomal rearrangements.With increased
understanding of the genetic and epigenetic makeup of high-risk pediatric leukemia has
come the opportunity to develop targeted therapies that promise to be both more effective
and less toxic than current chemotherapy. Of particular importance is an understanding of
the interconnections between different targets within the same cancer, and observations
of synergy between two different targeted therapies or between a targeted drug and con-
ventional chemotherapy. It has become clear that many cancers are able to circumvent
a single specific blockade, and pediatric leukemias are no exception in this regard. This
review highlights the most promising approaches to new drugs and drug combinations for
high-risk pediatric leukemia. Key biological evidence supporting selection of molecular tar-
gets is presented, together with a critical survey of recent progress toward the discovery,
pre-clinical development, and clinical study of novel molecular therapeutics.
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PEDIATRIC LEUKEMIA: THE NEED FOR TARGETED THERAPIES
This review focuses on pediatric leukemia, both acute lymphoblas-
tic leukemia (ALL) and acute myeloid leukemia (AML), which
together account for approximately one third of childhood can-
cers. ALL is primarily a childhood disease, whereas AML is much
more prevalent in adults (National Cancer Institute, 2010). How-
ever, due to its poorer prognosis, AML accounts for as many
childhood deaths per year as ALL. Aggressive treatment of chil-
dren with combinations of cytotoxic drugs has raised the 5-year
survival rate for pediatric ALL above 80%. Given that less than
one child in 10 survived ALL in the early 1960s, this is a remark-
able achievement. However, this progress has come at the cost of
severe toxicity, and nearly 20% of ALL cases either do not respond
or relapse following treatment. The 5-year survival rate for pedi-
atric AML is under 60%. AML that arises following treatment for
another malignancy (therapy-related AML) is particularly diffi-
cult to cure (Kurmasheva and Houghton, 2007; Pui et al., 2011b).
Figure 1 highlights how progress has slowed following a dramatic
improvement in survival from the 1950s–1980s.
In the past 30 years, few new anti-cancer agents have been
approved for use in pediatric patients. Survival in very high-risk
patient groups remains poor despite the most intensive cytotoxic
therapies. Rationally designed drugs have benefited adults with
cancer, but except in the case of BCR-ABL positive leukemias,
targeted therapies have so far done little to improve pediatric out-
comes. However, there are encouraging signs that this situation
is about to change. Study of the mechanistic basis for pediatric
cancer has begun to uncover defined molecular targets, raising the
possibility of treatment by specifically designed drugs (Mackall,
2011). In most cases of pediatric leukemia, the genetic profile is
well-defined, and patients at high risk of poor response to treat-
ment may be readily identified. However, this characterization of
leukemia by subtype generally has not led to much improvement in
outcome, due to an inability to develop effective new drugs because
of a lack of understanding of the biological mechanisms connect-
ing specific genetic abnormalities and leukemia progression (Pui
et al., 2011a). Readers are referred to recent reviews (Brandwein,
2011; Pui et al., 2011b) for current treatment regimens and clin-
ical outcomes. A notable exception to the dismal lack of success
in treating high-risk leukemia in children has been the remark-
able efficacy of the BCR-ABL kinase inhibitor imatinib (Gleevec)
in Philadelphia-positive (Ph+) ALL (Barr, 2010). In recent years
other points of intervention have been identified that may respond
to targeted drugs. This review highlights the biological evidence
pointing to novel specific molecular targets and the progress of
drug discovery efforts based on this evidence, especially for some
of the most intractable high-risk subtypes of ALL and AML.
MOLECULARLY TARGETED DRUG DISCOVERY AND
DEVELOPMENT
The approval of imatinib in 2001 to treat chronic myeloid leukemia
(CML) and its remarkable success rate – 90% 5-year survival –
spurred efforts to develop additional molecularly targeted thera-
pies for cancer and other diseases. The majority of this effort has
been directed toward adult disease, but an increased understand-
ing of the biology of pediatric cancer has fostered progress toward
targeted treatment of some of the most intractable cases (Brown
et al., 2009). The NCI lists 207 treatment clinical trials ongoing
for pediatric ALL and 188 for AML. (Note that the total number is
substantially less than 395 because trials for both ALL and AML are
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FIGURE 1 | Pediatric leukemia survival trends from 1950 to the present.
Data obtained from Kersey (1997) and Pui et al. (2011b).
counted twice.) Of these, 26 (13 both ALL and AML, 10 ALL and
3 AML) are testing molecularly targeted agents (National Can-
cer Institute, 2013). Numerous compound series are in earlier
stages of lead optimization and pre-clinical development. This
review is organized by broad disease targeting mechanisms, and
further subdivided by protein target classes. Numbers in bold type
in parentheses after compound names may be used to locate com-
pounds in Table 1, which summarizes the current roster of clinical
candidates and references the clinical protocol IDs (National Can-
cer Institute, 2013). The bold-type compound numbers also will
help the reader locate molecular structures depicted in Figures 2
and 3. Sections “Cell Proliferation and Apoptosis, Transcription,
and Chemokine Receptors and Stem Cell Homing” cover candi-
dates in clinical trials and highlight the most recent and innovative
examples of compounds in early discovery and pre-clinical devel-
opment. Several recent reviews cover specific targets and pathways,
and the reader is referred to these for more comprehensive cov-
erage. Although a majority of the agents under development are
aimed at arrest of cell proliferation and induction of apoptosis,
substantial work is also focused on modulation of transcription,
and homing of stem cells to the bone marrow.
CELL PROLIFERATION AND APOPTOSIS
Development of protein kinase inhibitors as therapeutic agents
for adult cancer has been an area of intense effort for many years.
Likewise, certain protein kinases in pediatric acute leukemia have
been targeted because they mediate cell signaling that promotes
growth and resists apoptosis. The most notable success has been
the inhibition of BCR-ABL, while much attention continues to be
focused on the receptor tyrosine kinase (RTK) FMS-like tyrosine
kinase-3 (FLT3), the mTOR/AKT pathway, JAK/STAT signaling,
and control of mitosis by aurora kinases (Figure 4). In addition
to protein kinases, the proteasome, and the anti-apoptotic pro-
tein BCL-2 are being targeted for inhibition to induce apoptosis in
pediatric leukemia.
Protein tyrosine kinases
BCR-ABL. The first example of a molecularly targeted therapy for
cancer was imatinib (1) (Gleevec), an inhibitor of the ABL tyrosine
kinase activity of the fusion protein BCR-ABL. This was initially
developed to treat CML in adults, but has since been shown to be
highly effective against Ph+ ALL in children, which also harbors
the BCL-ABL fusion (Schultz et al., 2009; Barr, 2010), and it was
recently approved by the FDA for this indication (Food and Drug
Administration, 2013). Since use of imatinib in children began, the
5-year survival rate for pediatric Ph+ ALL has more than doubled
to 80%. However, the appearance of mutant forms of the kinase
domain of BCR-ABL has led to resistance to imatinib (Hunger,
2011). Therefore, new series of inhibitors have been developed to
target mutant forms of the enzyme as well as the wild type. Dasa-
tinib (2) is currently in two Phase II trials for pediatric Ph+ ALL.
Nilotinib (3) binds 30-fold more tightly than imatinib to BCL-ABL
in resistant leukemia cells and is currently in Phase I pediatric tri-
als. However, neither dasatinib nor nilotinib are effective against
so-called gatekeeper mutations, notably T315I. This shortcom-
ing has been overcome by structure-based design of ponatinib,
which gave encouraging Phase I results in adult CML and Ph+
ALL (Cortes et al., 2012). A Phase II trial of ponatinib in Ph+ ALL
is due to start soon, but enrollment is limited to adult patients.
(See Figure 2A for structures of the compounds discussed in this
section.)
FLT3 and other RTKs. Receptor tyrosine kinases play an impor-
tant signal transduction role in acute leukemia. The FLT3 gene
is mutated in a significant proportion of high-risk pediatric ALL
and AML; activating FLT3 mutations occur in 22% of AML and
18% of MLL-rearranged ALL. AML harboring FLT3 internal tan-
dem duplications (FLT3-ITD) is associated with an especially
poor prognosis (Brown et al., 2006; Stubbs and Armstrong, 2007;
Swords et al., 2012). FLT3 mutations promote leukemia survival
and proliferation and block cell differentiation (Sexauer et al.,
2012). So far, FLT3 inhibitors have shown limited effectiveness
as single agent therapies, due to several confounding factors: low
plasma levels of compounds due to poor pharmacokinetics, lim-
ited efficacy due to high levels of competing FLT3 ligand (FL), and
point mutations arising in the inhibitor binding pocket (Grun-
wald and Levis, 2013). Intense effort is focused on optimizing
clinical response through design of improved compounds, adjust-
ment of dosage of conventional chemotherapy to attenuate FL
levels, and development of combination therapies. Currently, com-
pounds are in clinical trials as therapies to treat MLL-rearranged
leukemia (ALL and AML) and AML harboring FLT3-ITD (Daver
and Cortes, 2012). The staurosporine analog Lestaurtinib (4) is
being tested in MLL-rearranged infant ALL in a multicenter Phase
III trial in combination with conventional chemotherapy. A Phase
I/II dose-ranging trial of Midostaurin (5), another analog of the
natural product staurosporine, is ongoing in pediatric ALL and
AML. Other structural classes are also being tested. Sorafenib (6),
originally developed as a B-RAF inhibitor, also inhibits FLT3 and is
selectively cytotoxic to leukemia cells harboring FLT3 mutations.
It is currently in a Phase III trial in AML, as well as a Phase I trial in
combination with conventional chemotherapy. The most potent
FLT3 inhibitor in cells harboring FLT3-ITD is quizartinib (7), with
an IC50 of 1 nM (Kampa-Schittenhelm et al., 2013). It is currently
in a Phase I trial in relapsed or refractory ALL and AML. A recent
report describes BPR1J-097 (8), a FLT3 inhibitor in pre-clinical
development with selectivity and in vivo pharmacokinetics that
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Table 1 | Compounds currently in clinical trials as targeted drugs in pediatric ALL or AML.
Target class Target Section Compound
number*
Compound
name
Disease Trial
phase
Clinical protocol ID
Protein tyrosine kinases BCL-ABL BCR-ABL 2 Dasatinib ALL II CA180-226
2008-002260-33
NCT00777036
ALL II CA180-372
2011-001123-20
AALL1122
BCL-ABL BCR-ABL 3 Nilotinib ALL I CAMN107A2120
2010-018419-14
NCT01077544
FLT3 FLT3 and Other RTKs 4 Lestaurtinib ALL III CDR0000573996
COG-AALL0631
NCT00557193
FLT3 FLT3 and Other RTKs 5 Midostaurin ALL/AML I/II CPKC412A2114
2008-006931-11
NCT00866281
FLT3 FLT3 and Other RTKs 6 Sorafenib AML III NCI-2011-02670
COG-AAML1031
NCT01371981
ALL/AML I RELHEM
NCT00908167
FLT3 FLT3 and Other RTKs 7 Quizartinib ALL/AML I T2009-004
NCT01411267
Protein serine/threonine
kinases
mTOR mTOR 9 Rapamycin ALL II 10-007444
6137-09
NCT01162551
ALL/AML I CHP-755
CHP-IRB-2002-12-3086
NCT00068302
mTOR mTOR 10 Temsirolimus ALL I T2008-004
NCT01614197
ALL I NCI-2011-02679
COG-ADVL1114
NCT01403415
mTOR mTOR 11 Everolimus ALL I 11-237
NCT01523977
AKT AKT 13 MK-2206 ALL/AML I COG-ADVL1013
NCT01231919
JAK1/2 JAK1/2 14 Ruxolitinib ALL/AML I CDR0000680970
COG-ADVL1011
NCT01164163
Aurora A Aurora Kinases 17 Alisertib ALL/AML II CDR0000680512
COG-ADVL0921
NCT01154816
Aurora A/B Aurora Kinases 18 AT9283 ALL/AML I CRUK-CR0708-12
EUDRACT-2009-016952-36
NCT01431664
Proteases Proteasome Proteasome 20 Bortezomib AML III NCI-2011-02670
COG-AAML1031
NCT01371981
(Continued)
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Table 1 | Continued
Target class Target Section Compound
number*
Compound
name
Disease Trial
phase
Clinical protocol ID
ALL II 2008LS113
MT2008-33R
NCT01312818
ALL II CDR0000638413
COG-AALL07P1
NCT00873093
Anti-apoptotic proteins Bcl-2 Anti-Apoptotic
Protein BCL-2
23 Obatoclax ALL/AML I COG-ADVL0816
NCT00933985
DNA
methyltransferases
Various DNA
Methyltransferases
24 5-Azacytidine AML II J1240
P01CA015396
NCT01700673
Histone deacetylases Various Histone
Deacetylases
28 Vorinostat ALL/AML II NCT-2007-11-02-1004
NCT01422499
Various Histone
Deacetylases
29 Panobinostat ALL/AML I T2009-012
NCT01321346
Various Histone
Deacetylases
30 AR-42 AML I OSU-11130
NCI-2013-00122
NCT01798901
Chemokine receptors CXCR4 Chemokine
Receptors and Stem
Cell Homing
37 Plerixafor ALL/AML I POETIC Plerixafor
NCT01319864
*Refers to compound number in text and in Figures 2 and 3.
are apparently superior to those of earlier compound classes (Lin
et al., 2012).
In two very recent reports evidence of the involvement of
other RTKs in AML offers the possibility of additional mole-
cular targets: AXL was shown to activate FLT3 in AML (Park
et al., 2013), and siRNA knockdown of Mer reduced colony for-
mation and increased survival in mice (Lee-Sherick et al., 2013).
(See Figure 2B for structures of the compounds discussed in this
section.)
Protein serine/threonine kinases
mTOR. The PI3 kinase/AKT/mTOR pathway is activated in many
acute leukemias, and promotes leukemia cell survival and prolif-
eration (Barrett et al., 2012). Accordingly, mTOR inhibitors are
being tested as single agents and in combination with existing
chemotherapeutics. mTOR is a serine/threonine kinase, but the
approach to inhibition of this target has generally differed from
that of small-molecule active site-directed inhibitors employed
against other protein kinases. Current clinical studies are focused
on the macrolide natural product rapamycin and analogs, which
inhibit mTOR once complexed with FK-binding protein 12
(FKBP12). Rapamycin (9) (sirolimus) is in a Phase II ALL trial in
combination with methotrexate, and in Phase I studies in ALL and
AML as a single agent. Temsirolimus (10), an analog of sirolimus,
is being tested in combination with etoposide and cyclophos-
phamide in a Phase I ALL trial, and an ALL trial in combination
with several other chemotherapeutic agents is due to start soon.
Everolimus (11), another analog of sirolimus, is marketed for sev-
eral adult cancer indications. It is currently in a Phase I ALL trial in
combination with induction chemotherapy. A promising alterna-
tive to macrolide inhibition of the mTOR-FKBP12 complex is the
development of dual PI3 kinase/mTOR inhibitors (Martelli et al.,
2012). The ATP-binding pockets in the catalytic sites of PI3 kinase
and mTOR are structurally similar, allowing the development of
compounds that inhibit both enzymes. The dual PI3 kinase/mTOR
inhibitor NVP-BEZ235 (12) was originally developed for the treat-
ment of solid tumors (Maira et al., 2008), but it has recently
shown potent activity in ALL, and synergy with chemotherapeutic
agents, even in glucocorticoid-resistant cells (Schult et al., 2012).
(See Figure 2C for structures of the compounds discussed in this
section.)
AKT. AKT is a serine/threonine kinase functionally connected
with mTOR complexes that is a central component of signaling
through RTKs such as FLT3 (Park et al., 2010). Therefore, AKT
inhibition offers an approach to proliferative pathway suppression
that is complementary to inhibition of FLT3 or mTOR described
above. AKT inhibitors are being evaluated as single agents; MK-
2206 (13) is in Phase I trials in recurrent or refractory ALL and
AML. However, their most promising use could be as potentiators
of the efficacy of FLT3 inhibitors. Despite indisputable evidence
that FLT3 is a key driver in AML, and the discovery of potent, selec-
tive inhibitors, the clinical effectiveness of FLT3 inhibitors has been
modest. A significant reason for this appears to be that leukemia
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FIGURE 2 | Compounds targeting inhibition of cell proliferation or
induction of apoptosis. Numbers in bold type are used to refer to
compounds in this figure from the main text, Figure 4, andTable 1. (A)
BCR-ABL inhibitors, (B) FLT3 inhibitors, (C) mTOR inhibitors, (D) AKT inhibitor,
(E) JAK1/2 inhibitors, (F) aurora kinase inhibitors, (G) proteasome inhibitor,
(H) BCL-2 antagonists.
stem cells (LSCs) reside in the bone marrow, where they are pro-
tected from drug treatment. A high-throughput screen to test
investigational drug combinations in a co-culture of FLT-positive
AML and stromal cells found that MK-2206 (13) synergistically
potentiated the cytotoxic effect of the FLT3 inhibitor midostaurin
(5) (Weisberg et al., 2013).
An unexpected finding in the AKT pathway is that members of
the FOXO family of transcription factors enforce differentiation
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FIGURE 3 | Compounds targeting transcription or stem cell homing. Numbers in bold type are used to refer to compounds in this figure from the main text,
Figure 5, andTable 1. (A) DNA methyltransferase inhibitors, (B) histone deacetylase inhibitors, (C) DOT1L inhibitors, (D) BRD4 inhibitors, (E) Menin-binding
inhibitor, (F) CXCR4 antagonist.
blockade in AML (Sykes et al., 2011). The FOXOs are usually
considered to be tumor suppressors that are inhibited by AKT
through serine/threonine phosphorylation. However, in approx-
imately 40% of AML, AKT itself is repressed, and the FOXOs
are elevated and found to be essential to maintenance of an
undifferentiated state. Activation of AKT or deletion of the FOXOs
caused myeloid maturation and apoptosis in AML cells, but this
effect was countered by a resistance mechanism in which c-JUN
was activated, so a combination of FOXO and JNK (c-JUN N-
terminal kinase) inhibition may be an effective therapeutic strategy
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FIGURE 4 | Cell proliferation targets. Numerous interconnections
between targets and other cellular proteins are omitted for clarity. Numbers
in bold type refer to inhibitors shown in Figure 2.
(Sykes et al., 2011). (See Figures 2B,D for structures of the
compounds discussed in this section.)
JAK1/2. The JAK/STAT pathway is activated in certain high-risk
leukemias, especially Ph+-like ALL, leading to cell proliferation
and resistance to apoptosis (Maude et al., 2012). Activating muta-
tions of JAK kinases are also present in AML (Daver and Cortes,
2012). A Phase I clinical trial is underway to test a selective
JAK1/2 inhibitor, ruxolitinib (14). The aim is to select patients
with refractory or relapsed ALL or AML harboring JAK muta-
tions, although leukemia patient numbers may be limited because
the trial also includes patients with solid tumors. JAK inhibitors
may also be useful in combination with other targeted therapies.
The JAK2/FLT3 inhibitor pacritinib (15) demonstrated synergy
with the histone deacetylase (HDAC) inhibitor pracinostat (26)
in mouse AML models (Novotny-Diermayr et al., 2012). This
JAK2/HDAC inhibitor synergy may arise due to JAK2 possess-
ing an epigenetic function; in addition to its role in activation of
JAK-STAT signaling, JAK2 phosphorylates tyrosine 41 in histone
3 (H3Y41), leading to displacement of heterochromatin protein
1α. JAK inhibitors were also found to potentiate the cytotoxicity
of FLT3 inhibitors in a high-throughput screen of investigational
drug combinations in a co-culture of AML and stromal cells,
suggesting that JAK inhibitors may be effective in overcoming
the drug resistance of AML residing in the bone marrow (Weis-
berg et al., 2012). In a related study, discussed in Section “AKT”
above, the same research group observed synergy between AKT
and FLT3 inhibition. (See Figures 2E and 3B for structures of the
compounds discussed in this section.)
Aurora kinases. Aurora kinases A and B are serine/threonine
kinases that play a key role in the control of mitosis. Overexpres-
sion of these enzymes has been observed in pediatric leukemia
and is associated with a poor prognosis (Farag, 2011). Although
both enzymes have generated interest as targets, short hairpin RNA
knockdown, and corroboration using the selective aurora kinase B
inhibitor barasertib (16) suggested that antiproliferative and pro-
apoptotic effects are mediated predominantly through inhibition
of aurora kinase B (Hartsink-Segers et al., 2013). These findings
appear to be at odds with clinical progress to date with the selec-
tive aurora A inhibitor alisertib (17). Alisertib is currently in a
Phase II trial that includes refractory and relapsed ALL and AML
as well as pediatric solid tumors. Fragment-based drug discovery
was used to develop AT9283 (18), an inhibitor of aurora kinases
A and B and also JAK2. This compound was found to inhibit
growth and survival of patient-derived leukemia cells, associated
with a reduction in levels of phosphorylated FLT3 and inhibition
of downstream effectors such as ERK and MEK (Jayanthan et al.,
2013). On the basis of the encouraging pre-clinical results, AT9283
is being tested in relapsed and refractory ALL and AML in a Phase I
trial in the UK. A potentially important development is the discov-
ery of compounds that inhibit both FLT3 and aurora kinases; a dual
FLT3/aurora kinase inhibitor known simply as compound 27e (19)
may show enhanced clinical efficacy due to synergy between FLT3
and aurora kinase inhibition (Bavetsias et al., 2012). (See Figure 2F
for structures of the compounds discussed in this section.)
Proteasome
Bortezomib (20) is a highly potent proteasome inhibitor that pro-
tects tumor suppressor proteins from degradation. It is approved
and marketed for the treatment of multiple myeloma, but it also
promises to be effective in combination with other targeted thera-
pies and conventional chemotherapy in leukemia (Niewerth et al.,
2013). Combination of bortezomib with the HDAC inhibitor val-
proic acid (27) was effective against B-cell precursor ALL in cell
culture and mouse xenograft with or without simultaneous treat-
ment with chemotherapeutic agents. Evidence suggests that the
activity of the drug combination is mediated through modulation
of NF-κB activity, thereby promoting apoptosis (Bastian et al.,
2013). A Phase I trial in pediatric ALL and AML demonstrated
the effectiveness of bortezomib as a chemosensitizer in conjunc-
tion with chemotherapy, although not as a single agent (Horton
et al., 2007). Bortezomib is currently being tested in a Phase III
trial in AML, as well as in ALL in two Phase II combination tri-
als, one with the HDAC inhibitor vorinostat (28, see also “Histone
deacetylases”) together with dexamethasone, and the other with
combination chemotherapy. (See Figures 2G and 3B for structures
of the compounds discussed in this section.)
Anti-apoptotic protein BCL-2
Inhibition of the anti-apoptotic protein BCL-2 sensitizes cancer
cells to chemotherapy induced apoptosis (Fulda, 2009). In cell
lines and mouse xenografts derived from ALL patients, the BCL-
2 antagonist ABT-737 (21) demonstrated synergistic cytotoxicity
with standard chemotherapy (Kang et al., 2007). Furthermore, in
the pediatric pre-clinical testing program the orally bioavailable
BCL-2 antagonist navitoclax (22) (ABT-263) showed the great-
est efficacy against ALL among all the cancer models tested (Lock
et al., 2008). A recent study demonstrated cytotoxicity of the BCL-
2 antagonist obatoclax (23) in a broad range of patient-derived
infant ALL cell lines, and synergistic cell killing in combination
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with chemotherapeutic agents (Urtishak et al., 2013). The clinical
effectiveness of obatoclax combined with standard chemotherapy
is being tested in a Phase I trial in ALL and AML. (See Figure 2H
for structures of the compounds discussed in this section.)
TRANSCRIPTION
Inappropriate expression of specific genes caused by dysregulated
epigenetic modification appears to be a hallmark of many of the
most difficult to treat pediatric leukemias. Early work in this area
was focused on inhibition of DNA methyltransferases and histone
deacetylases (HDACs), due to the apparent role of these enzymes
in preventing expression of key tumor suppressor genes. Much
recent activity has been focused on histone methyltransferase,
bromodomain, and menin inhibition to suppress transcriptional
activation leading to elevated expression of specific oncogenes that
block differentiation of hematopoietic progenitors (Figure 5). An
epigenetic block of normal differentiation appears to be a key dri-
ver of pediatric leukemia harboring chromosomal rearrangements
that lead to fusion proteins, notably MLL fusions and NUP98-
NSD1 (Deshpande et al., 2012; Hatlen et al., 2012; Popovic and
Licht, 2012; Vu et al., 2013).
MLL fusions are the hallmark of an aggressive subtype of pedi-
atric ALL and AML known as mixed lineage leukemia, associated
with translocations of the MLL gene (Muntean and Hess, 2012).
These MLL rearrangements are especially prevalent in infant ALL,
occurring in 80% of cases, and also in 75% of therapy-related AML.
The 5-year survival rate for ALL without MLL rearrangement
approaches 90%; in stark contrast, infants with ALL harboring
MLL rearrangements have a very poor 40% survival rate (Robin-
son et al., 2009; Slany, 2009). The normal role of the MLL protein
is to modulate transcriptional elongation through histone methy-
lation. However, rearrangement of the MLL gene disrupts the
function of MLL by replacement of its C-terminal methyltrans-
ferase domain with a fusion protein. Fifty such fusion partners
are known, although 5 account for 80% of cases (Huret et al.,
2001; Meyer et al., 2006; Krivtsov and Armstrong, 2007). The
protein complex recruited by the MLL fusion activates transcrip-
tion of oncogenes critical for leukemic transformation, notably
HOXA9 and MEIS1 (Ayton and Cleary, 2003; Faber et al., 2009;
Mueller et al., 2009). Following early hematopoietic development,
FIGURE 5 |Transcriptional targets. Numerous interconnections between
targets and other proteins involved in transcriptional activation are omitted
for clarity. HDAC, histone deacetylase; DNMT, DNA methyltransferase.
Numbers in bold type refer to inhibitors shown in Figure 3.
expression of HOXA9 and MEIS1 is normally suppressed to allow
blood cell differentiation. Activated HOXA9 blocks differentiation
of hematopoietic progenitor cells, which instead acquire stem cell-
like character and the capacity for unlimited self renewal (Somer-
vaille and Cleary, 2010). Several components of the transcriptional
activation complex in MLL-R leukemia are being targeted: menin,
bromodomains, and the methyltransferase DOT1L (Figure 5).
The NUP98-NSD1 fusion protein occurs in a high-risk subtype
of AML following rearrangement of the genes NUP98 (nucle-
oporin, 98-kd component of nuclear pore complex) and NSD1
(nuclear receptor-binding SET domain protein 1). Since the first
case was identified 12 years ago (Jaju et al., 2001), it has become
clear that these genetic lesions are often missed by routine kary-
otyping. A recent comprehensive study using reverse transcription
polymerase chain reaction (RT-PCR) found NUP98-NSD1 in 4–
5% of pediatric AML, associated with a grim 4-year event-free
survival rate of <10% (Hollink et al., 2011). NSD1 is a his-
tone methyltransferase that regulates gene transcription through
methylation of lysine 36 in histone 3 (H3K36) (Morishita and di
Luccio,2011; Wagner and Carpenter, 2012). The methyltransferase
activity of NSD1 is retained in the NUP98-NSD1 fusion, and gives
rise to abnormally high levels of H3K36 methylation, enforcing
activation of transcription of oncogenes such as HOXA9. As in
MLL-R leukemia, elevated expression of HOXA9 in AML harbor-
ing NUP98-NSD1 blocks differentiation of blood cell progenitors,
leading them to acquire the capacity for unlimited self-renewal
and malignant transformation (Wang et al., 2007). Abolition of
the methyltransferase activity of NUP98-NSD1 by point mutation
demonstrated its essential role; the level of H3K36 methylation at
the HoxA9 locus was reduced, and mouse progenitor cells harbor-
ing NUP98-NSD1 underwent normal differentiation (Wang et al.,
2007). Therefore, inhibition of the methyltransferase activity of
NUP98-NSD1 may be a viable therapeutic strategy, although no
inhibitors of this fusion have been reported to date.
DNA methyltransferases
Elevated levels of DNA methylation lead to impaired expression
of tumor suppressor genes and other epigenetic changes that pro-
mote precancerous and cancerous conditions (Lyko and Brown,
2005). Two DNA methyltransferase inhibitors have been approved
for the treatment of myelodysplastic syndrome: 5-azacytidine (24)
and decitabine (25) (Fandy, 2009). These drugs have been evalu-
ated in clinical trials in AML, and decitabine received European
but not US approval in 2012 for treatment of adult AML. Two trials
in pediatric AML are pending: a Phase II trial focused on mainte-
nance therapy employing 5-azacytidine in combination with the
immunomodulatory biologic sargramostim, and a Phase I trial of
decitabine in combination with the HDAC inhibitor AR-42 (30,
see 2.2.2). (See Figures 3A,B for structures of the compounds
discussed in this section.)
Histone deacetylases
Acetylation of histones promotes transcription by increasing
accessibility of chromatin and exposing acetylated lysine residues
as key epigenetic markers that lead to recruitment of RNA poly-
merase. In the context of cancer, HDACs remove these acetyl
modifications, blocking expression of key tumor suppressor genes.
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Following numerous trials of HDAC inhibitors, two compounds
have been approved for the treatment of adult cancers (Giannini
et al., 2012). Currently, pediatric leukemia trials are underway to
test HDAC inhibitors as single agents and also in combination
with DNA methyltransferase inhibitors (Mummery et al., 2011).
Vorinostat (28) was the first HDAC inhibitor approved for clini-
cal use. It is a relatively simple molecule containing a zinc-binding
hydroxamic acid moiety that inhibits a broad spectrum of HDACs.
It is in Phase II pediatric testing in ALL and AML. A Phase I trial in
ALL and AML is also underway with panobinostat (29), another
broad-spectrum HDAC inhibitor containing a hydroxamic acid
group under development for various adult cancers. A Phase I
trial in AML is due to start soon combining the DNA methyl-
transferase inhibitor decitabine (25) with the HDAC inhibitor
AR-42 (30), which was reported to be superior to other broad-
spectrum HDAC inhibitors (Lucas et al., 2010). (See Figures 3A,B
for structures of the compounds discussed in this section.)
Histone methyltransferase DOT1L
Compelling evidence links recruitment of the histone methyl-
transferase DOT1L to transcriptional activation of oncogenes
such as HOXA9 in MLL-R leukemia (Bernt and Armstrong, 2011;
Zhang et al., 2012). The enzymatic activity of the histone methyl-
transferase DOT1L has been shown to be essential for MLL-R
leukemia in several studies. Conditional knockdown of Dot1l in
mice harboring the MLL-AF6 fusion inhibited leukemia progres-
sion (Deshpande et al., 2013), and the same group demonstrated
that Dot1l knockout prevented initiation of leukemia harboring
MLL-AF10 (Chen et al., 2012). An earlier study showed DOT1L
to be essential for HOXA9 and MEIS1 expression and the result-
ing leukemia driven by MLL-AF9 (Nguyen et al., 2011). DOT1L
knockdown has also been shown to induce apoptosis in cells
transformed with a variety of MLL fusions (Chang et al., 2010).
Therefore, efforts are underway to develop inhibitors of the enzy-
matic activity of DOT1L. DOT1L differs structurally from all other
histone lysine methyltransferases (HKMTs) in that it does not pos-
sess a SET domain comprising the catalytic site. This structural
uniqueness in the architecture of the catalytic site facilitates discov-
ery of selective inhibitors. Furthermore, DOT1L is the only enzyme
known to methylate lysine 79 on histone 3 (H3K79), reducing
the possibility of activation of an alternative cellular pathway to
circumvent a block to DOT1L-mediated methylation.
The most significant progress in the development of
DOT1L inhibitors has been made using structure-based and
mechanistically guided design based on the published X-ray
crystallographic structure of the catalytic domain of the enzyme
(Min et al., 2003). This approach led to EPZ004777 (31), a mimic
of the methyl donor substrate S-adenosylmethionine (SAM) that
inhibits DOT1L with high potency and selectivity. EPZ004777
displayed selective killing of MLL-R leukemia cell lines and sup-
pressed expression of the HOXA9 and MEIS1 oncogenes, con-
sistent with the proposed role of the enzyme target. Moreover,
despite poor pharmacokinetic properties, 7-day continuous infu-
sion of EPZ004777 resulted in a modest but significant increase
in survival in a mouse model of engrafted MLL-R leukemia. The
apparent uniqueness of DOT1L’s normal role had earlier raised
concerns that inhibitors would prove to be unacceptably toxic, but
evidence with EZ004777 suggested otherwise (Daigle et al., 2011).
Subsequently, the X-ray crystal structure of EPZ004777 bound to
DOT1L was solved, and the structural insights were used to incor-
porate a bromine substituent in the adenine ring to give SGC0946
(32). Compared to EPZ004777, SGC0946 showed an improved
KD of 60 pM, increased residence time on the enzyme due to a
slower dissociation rate, and improved cell permeability, leading
to greater efficacy in reducing intracellular H3K79 methylation
(Yu et al., 2012).
Identification of a hydrophobic pocket present in the SAM
binding site of DOT1L but absent in all other histone methyl-
transferases led to the design of a SAM mimic with two key
features: a benzyl moiety appended to the adenine ring to impart
selective binding, and replacement of the S-methyl group with
an N -iodoethyl group for irreversible covalent attachment to the
ε-amino group in lysine 79 of histone 3 (33). This compound
gave an IC50 of 110 nM and displayed >1000-fold selectivity
for DOT1L over other histone methyltransferases. However, the
mechanism of action of the compound was not studied to deter-
mine whether it reacted with the lysine-containing substrate as
predicted (Yao et al., 2011). A follow-up publication reported that
33 and other compounds containing a reactive N -iodoethyl group
did not show the desired selective killing of MLL-R leukemia
cells, so SAM analogs containing other S-methyl group replace-
ments were synthesized. The most potent of these were analogs
of EPZ004777 comprising the native adenine ring appended with
N6 substituents. Although some cellular activity was observed in
MLL-R leukemia cell lines, none of the compounds appeared to
offer advantages over EPZ00477 itself (Anglin et al., 2012).
Recently the possibility has arisen that MLL-R leukemia may
be targeted by blocking ubiquitinylation of histone 2B, preventing
activation of DOT1L. Following a demonstration that the activ-
ity of DOT1L is markedly enhanced by interaction of the enzyme
with ubiquitinylated histone 2B (McGinty et al., 2008, 2009), it
has now been reported that proliferation of MLL-R leukemia cells
was suppressed by knockdown of the ubiquitin ligase RNF20 that
ubiquitinylates histone 2B (Wang et al., 2013). (See Figure 3C for
structures of the compounds discussed in this section.)
Bromodomains
BRD4 is a member of the BET (bromodomain and extra-terminal
domain) family of proteins that binds to acetylated lysine in
histones via a structural motif known as a bromodomain. In
several cancers including acute leukemia, the resulting activation
of transcriptional elongation promotes the expression of growth-
promoting oncogenes (Deshpande et al., 2012; Popovic and Licht,
2012). An siRNA screen in AML cells revealed that inhibition
of BRD4 led to cell cycle arrest and apoptosis. Structure-based
design based on the X-ray crystal structure of the bromodomain
in BRD4 led to (+)-JQ1 (34), a potent and selective inhibitor of
binding of acetylated lysine (Filippakopoulos et al., 2010). (+)-
JQ1 suppressed proliferation of AML cells in culture and also
extended survival in a mouse model of AML (Zuber et al., 2011).
Subsequently (+)-JQ1 was shown to be cytotoxic to B-cell ALL
cell lines, especially those harboring rearrangements of CRLF2.
CRLF2 heterodimerizes with the IL7 receptor (IL7R) and dri-
ves proliferation and resistance to apoptosis. Strikingly, the genes
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most strongly downregulated by (+)-JQ1 were MYC and IL7R
(Ott et al., 2012). (+)-JQ1 also suppressed growth and induced
apoptosis in primary cells from patients with freshly diagnosed
and relapsed AML. Based on these promising results (+)-JQ1 will
be advanced to clinical trials (Herrmann et al., 2012). Another
bromodomain inhibitor, I-BET151 (35), optimized for selective
binding to BRD3/4 and good in vivo pharmacokinetics, gave a
promising increase in survival in two mouse models of MLL-R
leukemia (Dawson et al., 2011). The role of BRD4 in activation of
transcription became clearer and potentially more significant with
the discovery that it possesses protein kinase activity. BRD4 phos-
phorylates serine 2 on RNA polymerase II and thereby promotes
transcriptional initiation and elongation (Devaiah et al., 2012).
(See Figure 3D for structures of the compounds discussed in this
section.)
Menin and other proteins interacting with MLL fusions
Another approach to disruption of transcriptional activation in
MLL-R leukemia is to inhibit the interaction of MLL and menin.
Menin appears to be a central hub that interacts with MLL fusions
as well as wild type MLL and various other proteins to pro-
mote leukemia (Thiel et al., 2012). High-throughput screening
for inhibitors of binding of an MLL-derived peptide to menin
identified hits that were optimized for potency, leading to MI-2
(36). MI-2 was shown to disrupt the intracellular interaction of
menin and MLL-AF9 and arrest cell growth in MLL-R leukemia
cells, albeit with rather modest potency in the low micromo-
lar range. Moreover, MI-2 blocked the transforming ability of
MLL-AF9, suppressed the expression of the HOXA9 and MEIS1
oncogenes, and induced hematopoietic differentiation. No ani-
mal data has been reported so far; the intention is to optimize
the inhibitors further to enable assessment of their therapeutic
potential (Grembecka et al., 2012).
In addition to menin, various transcription factors and other
proteins interact with MLL fusions to form an activation com-
plex that promotes transcriptional elongation (Slany, 2009). In
principal, several protein–protein interactions in this complex
could be viable targets for disruption. One interaction that has
been validated as a target with a peptide, and is being screened
for small-molecule inhibitors, is the binding of MLL-AF4 to the
transcription factor AF9 (Watson et al., 2013). A direct AF4–
AF9 interaction has been demonstrated (Erfurth et al., 2004), and
shown to be essential for the survival of leukemia cell lines contain-
ing MLL-AF4 and MLL-AF9 fusions (Srinivasan et al., 2004). Yeast
two-hybrid assays identified the minimal amino acid sequence in
AF4 required for binding to AF9, and a cell-permeable peptide
derived from this sequence was shown to disrupt intracellular
AF4–AF9 binding. Moreover, this AF4-derived peptide killed cells
harboring MLL-AF4 and MLL-AF9 fusions but had no effect on
normal hematopoietic progenitor cells (Srinivasan et al., 2004).
(See Figure 3E for structure of the compound discussed in this
section.)
CHEMOKINE RECEPTORS AND STEM CELL HOMING
Antagonists of the chemokine receptor CXCR4 could be effec-
tive as chemosensitizing agents by preventing homing of LSCs
to the bone marrow. LSCs residing in the bone marrow evade
treatment by chemotherapeutic agents, resulting in resistance and
relapse (Attar, 2012; Peled and Tavor, 2013). Plerixafor (37) is
an antagonist of the CXCR4 chemokine receptor that has been
FDA approved since 2008 for hematopoietic stem cell mobiliza-
tion prior to transplantation in non-Hodgkin’s lymphoma and
multiple myeloma. Encouraging results were reported recently
from a Phase I trial of plerixafor in combination with cytarabine
and etoposide in adult AML (Uy et al., 2012) and a pediatric ALL
and AML trial is now underway. A recent report (Sison et al., 2013)
shows that CXCR4 antagonists may also synergize with other tar-
geted therapies; in a mouse model of infant MLL-R ALL, plerixafor
markedly enhanced the efficacy of the FLT3 inhibitor lestaurtinib
(4). (See Figures 2B and 3F for structures of the compounds
discussed in this section.)
CONCLUDING REMARKS
Based on a steady increase in understanding of the cellular mech-
anisms operating in high-risk pediatric leukemias, there is an
encouraging level of activity aimed at the discovery of targeted
therapies. Some of the molecular targets, such as protein kinases,
are already well established in adult cancers. In other cases, pedi-
atric leukemia research has led to novel targets that had not
previously attracted attention; a notable example is the histone
methyltransferase DOT1L. Given the number and diversity of new
chemical entities currently in pre-clinical and clinical development
for high-risk pediatric ALL and AML, the prospects are good for
significantly improved outcomes for children afflicted with these
cancers.
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